Healthcare / BiotechnologyKSE
$22150.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-147.7B · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.00T
P/E
N/A
•EV/EBITDA
19.2x
↑ROE
-7.7%
↓Gross Margin
27.9%
↓Debt/Equity
1.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
—
FCF margin
-5.1%
FCF / Net income
1.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.45T · net income $-69.51B · FCF $-125.76B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2451.48B | $2451.48B | $2204.86B | $2057.94B | $2079.56B |
| Net Income | $-69.51B | $-69.51B | $24.03B | $-54.14B | $32.82B |
| EBITDA | $125.72B | $125.72B | $212.83B | $66.84B | $145.56B |
| EPS | -1531.00 | -1531.00 | 529.00 | -1210.00 | 709.00 |
| Gross Margin | 27.9% | 27.9% | 28.1% | 29.3% | 33.6% |
| Operating Margin | 1.5% | 1.5% | -0.5% | -0.8% | 3.5% |
| Net Margin | -2.8% | -2.8% | 1.1% | -2.6% | 1.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.66 | 1.66 | 1.13 | 1.31 | 0.94 |
| Current Ratio | 0.94 | 0.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-125.76B | $-125.76B | $-147.67B | $-172.27B | $-30.02B |
| Returns | |||||
| ROE | -7.7% | -7.7% | 2.4% | -5.5% | 3.2% |
| Valuation | |||||
| P/E | — | — | 44.23 | — | 46.83 |
| EV/EBITDA | 19.24 | 19.24 | 9.92 | 37.49 | 15.81 |
| P/B | 1.12 | 1.12 | 1.07 | 1.43 | 1.48 |
| Growth & Yield | |||||
| Revenue Growth | 11.2% | 11.2% | 7.1% | -1.0% | — |
| EPS Growth | -389.4% | -389.4% | 143.7% | -270.7% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.5%
Start / end P/E
n/dx → n/dx
EPS bridge
529.00 → -1531.00
Residual
+12.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.